MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis
Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis
Journal Article

Serum citrullinated histone H3 as a biomarker of disease activity and renal outcome in microscopic polyangiitis and granulomatosis with polyangiitis

2026
Request Book From Autostore and Choose the Collection Method
Overview
Background Citrullinated histone H3 (CitH3), a hallmark component of neutrophil extracellular traps, has emerged as a circulating indicator of pathological neutrophil activation. We evaluated the utility of serum CitH3 as a biomarker for disease activity and risk of end-stage kidney disease (ESKD) development in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Methods A total of 65 patients with MPA and GPA were included. At diagnosis, serum CitH3 levels were measured and disease activity was assessed using the Birmingham Vasculitis Activity Score (BVAS). Correlation between serum CitH3 level and BVAS was assessed using Pearson’s correlation coefficient. Discriminatory performance of serum CitH3 for severe disease (BVAS ≥ 20) and low disease activity states (BVAS ≤ 3) was evaluated using receiver operating characteristic curve analysis. The association between serum CitH3 level and ESKD risk was assessed using multivariable Cox regression analysis. Results Serum CitH3 levels significantly correlated with BVAS ( r  = 0.393, p  = 0.001). Moreover, serum CitH3 demonstrated excellent discriminatory performance (area under the curve [AUC] 0.905, 95% confidence interval [CI] 0.825–0.984, p  < 0.001) for severe disease (BVAS ≥ 20), and acceptable discriminatory performance (AUC 0.703, 95% CI 0.558–0.848, p  = 0.013) for low disease activity states (BVAS ≤ 3). During a mean follow-up of 38.3 ± 32.8 months, eight (12.3%) patients developed ESKD. After adjusting for age and serum creatinine, higher serum CitH3 levels were independently associated with an increased risk of ESKD (adjusted hazard ratio 1.181, 95% CI 1.033–1.352, p  = 0.015). Conclusion Serum CitH3 correlated with disease activity, demonstrated strong discriminatory performance for severe disease and acceptable discriminatory performance for low disease activity states, and was associated with an increased risk of ESKD. These findings support serum CitH3 as a potential biomarker for identifying severe disease and low disease activity states, and stratifying ESKD risk in MPA and GPA.